Md Yuzaiful Md Yusof Yuz6Yusof
6 days 18 hours ago
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H
Nelly ZIADE 🍀 Nellziade
6 days 18 hours ago
Many drugs in the pipeline for #Systemic_Sclerosis
In particular, stay tuned for:
🔺Nerandomilast (PDE4i) in ILD
🔺CAR T cells (obviously): big RCT trials planned
🔺Bispecific T cell engagers: Teclistamab
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/I7HQtfwuW0
sheila RHEUMarampa
6 days 18 hours ago
Gecacitinib 100mg BiD vs PBO in active r-axSpA:
Met primary endpt ASAS40 at wk 16 showing efficacy of gecacitinib vs. PBO (51.9%vs12.9%,p<0.0001)
Gecacitinib showed ⬆️ improvements in ASDAS-CRP, physical fnxn, spinal mobility & QOL
Promising tx.
AbsOP0240 @RheumNow #EULAR2026 https://t.co/FytoRgxvnG
Mrinalini Dey DrMiniDey
6 days 18 hours ago
#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 18 hours ago
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At
Jiha Lee JihaRheum
6 days 18 hours ago
Personalized #RA treatment based on Ab status and early response: better than routine care? PRIMERA RCT (n=308) says not yet. b/tsDMARD use at 10m: 21% tailored vs 17% routine. Disease activity curves identical. MTX + T2T still the standard for most. @RheumNow #EULAR2026 POS0258 https://t.co/W9FVoqTcMq
Dr. John Cush RheumNow
1 week ago
CAR-T Cell Therapies in Refractory RMD Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed CAR-T cell therapy may https://t.co/lXX5RjEw6a
At EULAR 2026, two large phase 3 studies highlight that the JAK story in axSpA is still evolving rapidly, with different selectivity profiles and expanding global development programs continuing to push the field forward.
Md Yuzaiful Md Yusof Yuz6Yusof
1 week ago
#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN
At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.
Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an impact on our practice? Here is my selection of 3 abstracts presented at EULAR 2026 that identify therapeutic strategies that are well worth keeping on our radar.
